News & Updates
Filter by Specialty:
Metformin helps reduce ADT-related complications in prostate cancer patients
Metformin seems inadequate in reducing the risk of metabolic syndrome (MS) in patients with prostate cancer receiving androgen deprivation therapy (ADT), results of the PRIME study have shown.
Metformin helps reduce ADT-related complications in prostate cancer patients
29 Oct 2025
ICON8B OS data support a new SoC for epithelial ovarian cancer
In the final overall survival (OS) analysis of the phase III ICON8B trial, first-line treatment with bevacizumab in combination with a chemotherapeutic regimen comprising carboplatin Q3W and dose-dense paclitaxel QW improved survival in women with high-risk stage III-IV epithelial ovarian cancer.
ICON8B OS data support a new SoC for epithelial ovarian cancer
29 Oct 2025
Nivolumab bests ipilimumab in head-to-head melanoma trial
The final, long-term results from the phase III CheckMate 238 trial continue to show the superior recurrence-free survival (RFS) benefit of adjuvant nivolumab (NIVO) over ipilimumab (IPI) for resected stage IIIB-C or IV melanoma.
Nivolumab bests ipilimumab in head-to-head melanoma trial
28 Oct 2025
Enzalutamide-ADT a win for biochemically recurrent prostate cancer
In the final overall survival (OS) analysis of the phase III EMBARK trial, the combination of enzalutamide and androgen deprivation therapy (ADT; leuprolide acetate) delivers a significant OS benefit in men with high-risk biochemically recurrent (hrBCR) prostate cancer without evidence of metastases on conventional imaging.